Vimarsana
Biggest News Aggregation in the World

Page 4 - Patient Selection News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patient Selection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patient Selection Today - Breaking & Trending Today

Artificial Intelligence (AI) In Clinical Trials Market - Vimarsana News

Artificial Intelligence (AI) In Clinical Trials Market

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032...

Mixed, 'Intriguing' Result for Stroke Neuroprotective Agent - Vimarsana News

Mixed, 'Intriguing' Result for Stroke Neuroprotective Agent

Two new studies of the potential neuroprotective agent nerinetide for patients with acute ischemic stroke have shown conflicting results, with suggestions of benefit when given very early in the prehospital setting.

Relapsed/Refractory Follicular Lymphoma: EZH2- and PIK3-Targeted Therapies - Vimarsana News

Relapsed/Refractory Follicular Lymphoma: EZH2- and PIK3-Targeted Therapies

A brief discussion on the respective roles of EZH2- and PI3K-targeted therapies in patients with relapsed/refractory follicular lymphoma.

HUTCHMED Highlights Presentation of Results from the Phase - Vimarsana News

HUTCHMED Highlights Presentation of Results from the Phase

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today...

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer - Vimarsana News

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 -- HUTCHMED Limited ; class='js-l-obf link link--blue'